Pharmaceuticals company Neuland Laboratories announced Q1FY25 results:
- Total Income: Rs 444.4 crore, reflecting a YoY growth of 21.7% compared to Q1FY24 (Rs 365.0 crore) and a QoQ growth of 13.8% from Q4FY24 (Rs 390.4 crore).
- EBITDA: Rs 128.6 crore, representing a 29.5% increase from Q1FY24 (Rs 99.3 crore) and a 14.7% rise from Q4FY24 (Rs 112.2 crore).
- EBITDA Margin: 28.9%, an increase of 174 basis points from Q1FY24 (27.2%) and a slight increase of 21 basis points from Q4FY24 (28.7%).
- Exceptional Item: Rs 20.6 crore (noted for the quarter).
- Profit After Tax (PAT): Rs 98.3 crore, up 58.0% from Q1FY24 (Rs 62.2 crore) and a 45.5% increase from Q4FY24 (Rs 67.6 crore).
- PAT Margin: 22.1%, a growth of 510 basis points compared to Q1FY24 (17.0%) and up 480 basis points from Q4FY24 (17.3%).
- Earnings Per Share (EPS): Rs 76.6, reflecting a 58.0% increase from Q1FY24 (Rs 48.5) and a 45.5% rise from Q4FY24 (Rs 52.7).
Commenting on the performance Sucheth Davuluri, Vice-Chairman and Chief Executive Officer of the Company said, “We recorded our highest ever quarterly revenues in Q1FY25 led by growth in the CMS business even as we recorded healthy EBITDA margins. We continue to maintain that FY25 will be a year of normalisation of revenue growth and subsequently margins as we continue to invest for growth. We expect our business to regain momentum from FY26 onwards basis our visibility from our portfolio of projects and products.”
In addition, Saharsh Davuluri, Vice Chairman and Managing Director, Neuland Laboratories added “The CMS revenues were driven by commercial molecules in line with our expectations as we outline our strategy over the years. As we evaluate our pipeline of projects and the flow of new projects, we remain enthusiastic on the strong potential of the CMS business over the long term. The GDS business continues to build on the strong base we have with quality focussed customers, even as our R&D team is working on an exciting set of molecules to add to our portfolio.”